Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02341105
Other study ID # AmioCaAF1
Secondary ID
Status Terminated
Phase Phase 4
First received
Last updated
Start date January 2016
Est. completion date January 2018

Study information

Verified date February 2021
Source Population Health Research Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Randomized trial of low-dose amiodarone therapy versus catheter ablation (CA) in older patients with persistent atrial fibrillation (AF). Primary Objective: To compare amiodarone to catheter ablation in patients aged 50 to 80 years with symptomatic AF for the composite outcome of hospitalization for cardiovascular cause or emergency department visit for atrial arrhythmia


Description:

This is a single centre vanguard phase prospective randomized open label study with blinded outcome adjudication. Patients will be randomized by a central randomization system (1:1) to amiodarone or catheter ablation. 1. Amiodarone will be started at a dose of 400 mg/day. After one month the dose will be lowered to 200 mg per day. Patients will be seen every six months. At each visit the dose of amiodarone will be lowered by 100 mg per week if the patient is having a good clinical response to treatment. Good clinical response will be a a clinical assessment that takes into account not only actual or possible arrhythmia recurrence but also side-effects and patient acceptability of treatment. A minimum dose of 700 mg/week will be allowed. If patient symptoms recur, the amiodarone dose may be increased but not above a dose of 200 mg/day . 2. Catheter ablation of persistent AF will be done within two months using pulmonary vein isolation in all subjects 3. Patient not in sinus rhythm at time randomization will undergo DC cardioversion after at least 1 month of amiodarone Rx or during CA. Follow up: Clinical assessment will include a medical history and physical examination to be performed at baseline, and every 3 months. This will also include 12-lead ECG. b. At 3, 6, 12, 18, and 24 months: QOL questionnaire (AFEQT- Atrial Fibrillation Effect on QualiTy of life) c. Thyroid and liver function tests, chest X-ray will be obtained at regular intervals. d. Arrhythmia will be monitored using a 2-week event monitors at 6, 12, 18, 24 months.


Recruitment information / eligibility

Status Terminated
Enrollment 10
Est. completion date January 2018
Est. primary completion date January 2018
Accepts healthy volunteers No
Gender All
Age group 50 Years to 80 Years
Eligibility Inclusion Criteria: 1. Recurrent symptomatic Atrial Fibrillation (AF) 2. Age 50-80 years with persistent AF (=1 of AF episode lasting more than a week or requiring cardioversion) Exclusion Criteria: 1. Permanent atrial fibrillation 2. Prior continuous use of amiodarone of more than 2 weeks. 3. Prior catheter ablation for AF. 4. Have a documented resting heart (while awake) of < 50 beats per minute. 5. Have a known severe liver disease. 6. Are deemed not suitable for CA (LA size, comorbidities…). 7. Have a severe valvular disease or have a mechanical mitral prosthesis. 8. Have a life-expectancy of less than 2 years.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Catheter ablation
Pulmonary vein isolation by catheter ablation
Drug:
Amiodarone
antiarrhythmic therapy using Amiodarone

Locations

Country Name City State
Canada Hamilton Health Sciences Hamilton Ontario

Sponsors (2)

Lead Sponsor Collaborator
Population Health Research Institute Hamilton Health Sciences Corporation

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Other Potential Side Effects Related to amiodarone or ablation procedure Known potential side effects of catheter ablation include vascular access complications such as hematoma, pseudoaneurysm, or AV fistula. Less common but more serious include cardiac perforation (0.5%-1%) and thromboembolism (0.5%-1%), and fatal complications occur in approximately 1:1000 cases.
Known potential side effects of amiodarone include amiodarone toxicity, corneal micro-deposits, photosensitivity, thyroid abnormalities. pulmonary toxicity, abnormal liver function, and skin discolouration.
2 years
Primary The composite outcome of hospitalization for cardiovascular cause or emergency department visit for atrial arrhythmia. 2 years
Secondary First recurrence of an atrial tachyarrhythmia documented on 12 lead ECG or a 14-day event monitor 2 years
Secondary First recurrence of a symptomatic atrial tachyarrhythmia documented on 12 lead ECG or a 14-day event monitor 2 years
Secondary Quality of life measured at 3, 6 and 12 months using the Atrial Fibrillation Effect on QualiTy of Life Survey (AFEQT) 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Completed NCT04571385 - A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF) Phase 2
Terminated NCT04115735 - His Bundle Recording From Subclavian Vein
Completed NCT05366803 - Women's Health Initiative Silent Atrial Fibrillation Recording Study N/A
Completed NCT02864758 - Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
Recruiting NCT05442203 - Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart Disease N/A
Completed NCT05599308 - Evaluation of Blood Pressure Monitor With AFib Screening Feature N/A
Completed NCT03790917 - Assessment of Adherence to New Oral anTicoagulants in Atrial Fibrillation patiEnts Within the Outpatient registrY
Enrolling by invitation NCT05890274 - Atrial Fibrillation (AF) and Electrocardiogram (EKG) Interpretation Project ECHO N/A
Recruiting NCT05266144 - Atrial Fibrillation Patients Treated With Catheter Ablation
Recruiting NCT05316870 - Construction and Effect Evaluation of Anticoagulation Management Model in Atrial Fibrillation N/A
Not yet recruiting NCT06023784 - The Impact of LBBAP vs RVP on the Incidence of New-onset Atrial Fibrillation in Patients With Atrioventricular Block N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Recruiting NCT04092985 - Smart Watch iECG for the Detection of Cardiac Arrhythmias
Completed NCT04087122 - Evaluate the Efficiency Impact of Conducting Active Temperature Management During Cardiac Cryoablation Procedures N/A
Completed NCT06283654 - Relieving the Emergency Department by Using a 1-lead ECG Device for Atrial Fibrillation Patients After Pulmonary Vein Isolation
Recruiting NCT05416086 - iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study N/A
Completed NCT05067114 - Solutions for Atrial Fibrillation Edvocacy (SAFE)
Completed NCT04546763 - Study Watch AF Detection At Home
Completed NCT03761394 - Pulsewatch: Smartwatch Monitoring for Atrial Fibrillation After Stroke N/A